These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19025367)

  • 1. Nonnucleotide reverse-transcriptase inhibitors and treatment interruption.
    DiNubile MJ
    Clin Infect Dis; 2008 Dec; 47(12):1602; author reply 1603. PubMed ID: 19025367
    [No Abstract]   [Full Text] [Related]  

  • 2. Resistance: a shifting paradigm.
    Jenny-Avital ER
    AIDS Clin Care; 2002 Dec; 14(12):106. PubMed ID: 12510656
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibitors of HIV-1 reverse transcriptase.
    Ilina T; Parniak MA
    Adv Pharmacol; 2008; 56():121-67. PubMed ID: 18086411
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection.
    Katzenstein DA
    AIDS Read; 2008 Sep; 18(9):478-9. PubMed ID: 18828232
    [No Abstract]   [Full Text] [Related]  

  • 5. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent methamphetamine use, primary NNRTI resistance.
    Carter M
    IAPAC Mon; 2007 Jan; 13(1):12. PubMed ID: 17523245
    [No Abstract]   [Full Text] [Related]  

  • 7. HIV drug resistance.
    Calmy A; Pascual F; Ford N
    N Engl J Med; 2004 Jun; 350(26):2720-1. PubMed ID: 15215494
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs for HIV infection.
    Medical Letter Inc
    Treat Guidel Med Lett; 2006 Oct; 4(50):67-76. PubMed ID: 16985490
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent highlights in clinical AIDS research.
    Laurence J
    AIDS Read; 2008 Feb; 18(2):64-6. PubMed ID: 18330032
    [No Abstract]   [Full Text] [Related]  

  • 10. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the changing prevalence of K65R.
    Theys K; Vandamme AM
    AIDS Rev; 2008; 10(2):125. PubMed ID: 18615124
    [No Abstract]   [Full Text] [Related]  

  • 12. The utility of nucleos(t)ide-only regimens in the treatment of Mycobacterium tuberculosis-HIV-1 coinfection.
    Armstrong-James D; Menon-Johansson A; Pozniak A
    AIDS; 2009 Apr; 23(7):865-7. PubMed ID: 19307940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delavirdine (Rescriptor).
    Res Initiat Treat Action; 2000 Mar; 6(1):20-1. PubMed ID: 11708180
    [No Abstract]   [Full Text] [Related]  

  • 14. Zalcitabine (Hivid).
    Res Initiat Treat Action; 2000 Mar; 6(1):10-1. PubMed ID: 11708175
    [No Abstract]   [Full Text] [Related]  

  • 15. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Researcher presents vexing information on rilpivirine.
    Dalton P
    Proj Inf Perspect; 2008 Sep; (46):10-2. PubMed ID: 19048650
    [No Abstract]   [Full Text] [Related]  

  • 18. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of drug-resistant HIV-1 is stabilizing in Europe.
    Vercauteren J; Wensing AM; van de Vijver DA; Albert J; Balotta C; Hamouda O; Kücherer C; Struck D; Schmit JC; Asjö B; Bruckova M; Camacho RJ; Clotet B; Coughlan S; Grossman Z; Horban A; Korn K; Kostrikis L; Nielsen C; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Riva C; Ruiz L; Salminen M; Schuurman R; Sonnerborg A; Stanekova D; Stanojevic M; Vandamme AM; Boucher CA
    J Infect Dis; 2009 Nov; 200(10):1503-8. PubMed ID: 19835478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.